C

Caladrius Biosciences Inc
LSE:0HS8

Watchlist Manager
Caladrius Biosciences Inc
LSE:0HS8
Watchlist
Price: 2.35 USD 4.5% Market Closed
Market Cap: 45.5m USD
Have any thoughts about
Caladrius Biosciences Inc?
Write Note
Section:
 

Profitability Summary

Caladrius Biosciences Inc's profitability score is 21/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

21/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

21/100
Profitability
Score
21/100
Profitability
Score

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Revenue
+
Growth Rates:
1 Year
-
3 Years
-
5 Years
-
7 Years
-
10 Years
-94%
Operating Income
+
Growth Rates:
1 Year
+13%
3 Years
+23%
5 Years
-12%
7 Years
+19%
10 Years
+61%
Net Income
+
Growth Rates:
1 Year
+4%
3 Years
+27%
5 Years
-3%
7 Years
-
10 Years
+64%

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Caladrius Biosciences Inc

Revenue
1m USD
Operating Expenses
-23.4m USD
Operating Income
-22.4m USD
Other Expenses
2.4m USD
Net Income
-20m USD

Margins Comparison
Caladrius Biosciences Inc Competitors

Country Company Market Cap Operating
Margin 		Net
Margin
US
Caladrius Biosciences Inc
LSE:0HS8
45.5m USD
-2 241%
-1 999%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
-21 040%
US
Abbvie Inc
NYSE:ABBV
382.5B USD
29%
8%
US
Amgen Inc
NASDAQ:AMGN
175.8B USD
22%
12%
US
Gilead Sciences Inc
NASDAQ:GILD
146B USD
38%
2%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
128.5B USD
40%
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
-392%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.6B USD
30%
31%
AU
CSL Ltd
ASX:CSL
121.1B AUD
26%
18%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
-33%
NL
argenx SE
XBRU:ARGX
31.8B EUR
-1%
38%
No Stocks Found

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Caladrius Biosciences Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
US
Caladrius Biosciences Inc
LSE:0HS8
45.5m USD
-51%
-45%
-58%
-1 023%
FR
Pharnext SCA
OTC:PNEXF
6T USD
115%
-391%
275%
3 093%
US
Abbvie Inc
NYSE:ABBV
382.5B USD
62%
3%
17%
20%
US
Amgen Inc
NASDAQ:AMGN
175.8B USD
68%
4%
10%
10%
US
Gilead Sciences Inc
NASDAQ:GILD
146B USD
2%
1%
22%
15%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
128.5B USD
-3%
-2%
23%
-102%
US
Epizyme Inc
F:EPE
94.1B EUR
-877%
-67%
-73%
-182%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.6B USD
16%
12%
13%
65%
AU
CSL Ltd
ASX:CSL
121.1B AUD
15%
7%
12%
9%
US
Seagen Inc
F:SGT
39.3B EUR
-28%
-21%
-27%
-39%
NL
argenx SE
XBRU:ARGX
31.8B EUR
20%
18%
0%
-11%
No Stocks Found

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Summary
0HS8 intrinsic value, competitors valuation, and company profile.
DCF Valuation
0HS8 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
0HS8 stock valuation using valuation multiples.
Wall Street Estimates
0HS8 price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
0HS8 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 236,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.